These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 4782297)

  • 1. Procaine: a monoamine oxidase inhibitor in schizophrenia.
    Bucci L
    Dis Nerv Syst; 1973; 34(7):389-91. PubMed ID: 4782297
    [No Abstract]   [Full Text] [Related]  

  • 2. The use of monoamine oxidase inhibitors in schizophrenia.
    Brenner R; Shopsin B
    Biol Psychiatry; 1980 Aug; 15(4):633-47. PubMed ID: 7397294
    [No Abstract]   [Full Text] [Related]  

  • 3. Orthostatic effects of an amine oxidase inhibitor (W3207B).
    Freeman H; Karacan I; Waterman WE; Khan AU; Zimmer FL; Feldstein A; Tedeschi CG; DeFelice EA
    Int J Neuropsychiatry; 1965 Oct; 1(5):513-7. PubMed ID: 5858891
    [No Abstract]   [Full Text] [Related]  

  • 4. Effects of a selective inhibitor of type A monoamine oxidase--Lilly 51641--on behavior, sleep and circadian rhythms in depressed and schizophrenic patients.
    Carman JS; Gillin JC; Murphy DL; Weinberger DR; Kleinman JE; Bigelow LB; Wyatt RJ
    Commun Psychopharmacol; 1978; 2(6):513-23. PubMed ID: 371909
    [No Abstract]   [Full Text] [Related]  

  • 5. Monoamino oxidase inhibitors and schizophrenia.
    Bucci L
    Dis Nerv Syst; 1967 Jan; 28(1):55-9. PubMed ID: 5334844
    [No Abstract]   [Full Text] [Related]  

  • 6. Gerovital H3 in the treatment of the depressed aging patient.
    Cohen S; Ditman KS
    Psychosomatics; 1974; 15(1):15-9. PubMed ID: 4606585
    [No Abstract]   [Full Text] [Related]  

  • 7. A preliminary study of Lilly 51641.
    Simpson GM; Iqbal J; Iqbal F
    Curr Ther Res Clin Exp; 1966 Aug; 8(8):400-5. PubMed ID: 4958157
    [No Abstract]   [Full Text] [Related]  

  • 8. Efficacy of selegiline add on therapy to risperidone in the treatment of the negative symptoms of schizophrenia: a double-blind randomized placebo-controlled study.
    Amiri A; Noorbala AA; Nejatisafa AA; Ghoreishi A; Derakhshan MK; Khodaie-Ardakani MR; Hajiazim M; Raznahan M; Akhondzadeh S
    Hum Psychopharmacol; 2008 Mar; 23(2):79-86. PubMed ID: 17972359
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical trial of a new type promptly acting psychoenergetic agent (phenyl-isopropyl-methylpropinyl-HCl, "E-250").
    Varga E; Tringer L
    Acta Med Acad Sci Hung; 1967; 23(3):289-95. PubMed ID: 6056555
    [No Abstract]   [Full Text] [Related]  

  • 10. The mono-amine oxidase inhibitors; their usefulness and their safety.
    Bucci L
    Dis Nerv Syst; 1969 Dec; 30(12):843-7. PubMed ID: 5369136
    [No Abstract]   [Full Text] [Related]  

  • 11. The effect of augmentation with moclobemide on symptoms of schizophrenia.
    Silver H; Aharon N; Hausfater N; Jahjah N
    Int Clin Psychopharmacol; 1999 May; 14(3):193-5. PubMed ID: 10435775
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A look at Gerovital--the "youth" drug.
    Kent S
    Geriatrics; 1976 Dec; 31(12):95-6, 101-2. PubMed ID: 1001903
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Use of a combination of methionine and various psychotropic drugs in the treatment of chronic schizophrenia patients].
    Matveĭchuk TS
    Zh Nevropatol Psikhiatr Im S S Korsakova; 1969; 69(12):1868-71. PubMed ID: 5375564
    [No Abstract]   [Full Text] [Related]  

  • 14. Psychodynamic aspects in the use of monoamine oxidase inhibitor antidepressants.
    Roskos SR; Takahashi T
    Bull Menninger Clin; 1981 Mar; 45(2):143-8. PubMed ID: 7260455
    [No Abstract]   [Full Text] [Related]  

  • 15. The psychiatrist and MAO inhibitors.
    Bucci L
    Dis Nerv Syst; 1968 Feb; 29(2):127-30. PubMed ID: 5637593
    [No Abstract]   [Full Text] [Related]  

  • 16. Schizophrenia, psychotropic medication, and cataract.
    McCarty CA; Wood CA; Fu CL; Livingston PM; Mackersey S; Stanislavsky Y; Taylor HR
    Ophthalmology; 1999 Apr; 106(4):683-7. PubMed ID: 10201587
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The dyskenesias: a new therapeutic approach.
    Bucci L
    Dis Nerv Syst; 1971 May; 32(5):324-7. PubMed ID: 4931496
    [No Abstract]   [Full Text] [Related]  

  • 18. An open multicenter study of the efficacy of MDL 72,974A, a monoamine oxidase type B (MAO-B) inhibitor, in Parkinson's disease.
    Myllylä VV; Sotaniemi KA; Aasly J; Sjaastad O; Rinne U; McIntyre T; Cremer G
    Adv Neurol; 1993; 60():676-80. PubMed ID: 8420209
    [No Abstract]   [Full Text] [Related]  

  • 19. [Monoamine oxidase inhibitors in clinical anesthesia].
    Fujita T; Miyazaki M
    Masui; 1970 Jul; 19(7):695-703. PubMed ID: 5465310
    [No Abstract]   [Full Text] [Related]  

  • 20. Mono-amine oxidase inhibitors and schizophrenia.
    Price J; Hopkinson G
    Psychiatr Clin (Basel); 1968; 1(2):65-84. PubMed ID: 4878603
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.